Despite many recent advances in prevention and treatment interventions for HIV and substance use, policymakers and providers have been forced to confront a persistent insufficiency of funds and to make difficult choices from among competing claims on scarce resources. In this renewal application, we propose to continue our work to address emerging questions about global HIV prevention, treatment, and priority setting in substance-using populations. We will extend our prior epidemiologic modeling work by assessing portfolios of prevention and treatment interventions, by addressing these interventions in the context of co-epidemics (HIV, hepatitis C virus infection, and tuberculosis), and by developing resource allocation tools. The goal of our work is to use epidemiologic modeling to help decision makers optimize population health by providing information on the comparative effectiveness, cost-effectiveness, and affordability of alternative portfolio investments.
Our aims are: 1. To estimate production functions that characterize the relationship between program expenditures and health-related outcomes, such as reductions in transmission risk for prevention programs and the delivery of services for treatment programs. 2. To develop model-based methods to translate the behavioral and biological impact of HIV-related interventions into epidemic outcomes, such as infections averted and years of life saved. 3. To determine how best to estimate health outcomes, costs, and cost-effectiveness of HIV and substance use interventions (for example, in the presence of co-epidemics). 4. To assess the individual- and population-level effectiveness, cost, cost-effectiveness, and budget impact of specific interventions aimed at preventing and treating HIV and substance use and related co-epidemics (e.g., HIV, HCV, and tuberculosis). 5. To inform the allocation of societal resources by examining the effectiveness and cost- effectiveness of portfolios of prevention and treatment interventions in the context of the regional epidemiology of disease. 6. To develop practical resource allocation tools for policymakers to assist them in making informed investments of resources in HIV and substance use treatment and prevention programs. Our proposed research will develop innovative epidemiologic modeling methods for assessing portfolios of interventions;critically evaluate promising prevention and treatment interventions;advance the state of the art in HIV planning and policy modeling;and provide planners with innovative tools to assist them in informed allocation of scarce resources for HIV and substance use prevention and treatment. The proposed work will enable us to have broad impact on HIV and substance use policy in the U.S. and internationally.

Public Health Relevance

The goal of our work is to use epidemiologic modeling to help decision makers optimize population health by providing information on the comparative effectiveness, cost-effectiveness, and affordability of interventions for HIV and substance use. Our proposed research will develop innovative epidemiologic modeling methods for assessing portfolios of interventions;critically evaluate promising prevention and treatment interventions;advance the state of the art in HIV planning and policy modeling;and provide planners with innovative tools to assist them in informed allocation of scarce resources for HIV and substance use prevention and treatment.

Agency
National Institute of Health (NIH)
Institute
National Institute on Drug Abuse (NIDA)
Type
Research Project (R01)
Project #
5R01DA015612-12
Application #
8651905
Study Section
AIDS Clinical Studies and Epidemiology Study Section (ACE)
Program Officer
Hartsock, Peter
Project Start
2002-09-25
Project End
2018-01-31
Budget Start
2014-02-01
Budget End
2015-01-31
Support Year
12
Fiscal Year
2014
Total Cost
Indirect Cost
Name
Stanford University
Department
Internal Medicine/Medicine
Type
Schools of Medicine
DUNS #
City
Stanford
State
CA
Country
United States
Zip Code
94304
Reddy, Krishna P; Kong, Chung Yin; Hyle, Emily P et al. (2017) Lung Cancer Mortality Associated With Smoking and Smoking Cessation Among People Living With HIV in the United States. JAMA Intern Med 177:1613-1621
Gonsalves, Gregg S; Paltiel, A David; Cleary, Paul D et al. (2017) A Flow-Based Model of the HIV Care Continuum in the United States. J Acquir Immune Defic Syndr 75:548-553
Walensky, Rochelle P; Borre, Ethan D; Bekker, Linda-Gail et al. (2017) Do Less Harm: Evaluating HIV Programmatic Alternatives in Response to Cutbacks in Foreign Aid. Ann Intern Med 167:618-629
Liu, Shan; Brandeau, Margaret L; Goldhaber-Fiebert, Jeremy D (2017) Optimizing patient treatment decisions in an era of rapid technological advances: the case of hepatitis C treatment. Health Care Manag Sci 20:16-32
Suen, Sze-Chuan; Brandeau, Margaret L; Goldhaber-Fiebert, Jeremy D (2017) Optimal timing of drug sensitivity testing for patients on first-line tuberculosis treatment. Health Care Manag Sci :
Suen, Sze-Chuan; Goldhaber-Fiebert, Jeremy D; Brandeau, Margaret L (2017) Risk stratification in compartmental epidemic models: Where to draw the line? J Theor Biol 428:1-17
Glaubius, Robert L; Hood, Greg; Penrose, Kerri J et al. (2016) Cost-effectiveness of Injectable Preexposure Prophylaxis for HIV Prevention in South Africa. Clin Infect Dis 63:539-47
Chahal, Harinder S; Marseille, Elliot A; Tice, Jeffrey A et al. (2016) Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med 176:65-73
Gilbert, Jennifer A; Shenoi, Sheela V; Moll, Anthony P et al. (2016) Cost-Effectiveness of Community-Based TB/HIV Screening and Linkage to Care in Rural South Africa. PLoS One 11:e0165614
Bendavid, Eran (2016) Past and Future Performance: PEPFAR in the Landscape of Foreign Aid for Health. Curr HIV/AIDS Rep 13:256-62

Showing the most recent 10 out of 135 publications